D-1539-2022 Class II Terminated

Recalled by Teva Pharmaceuticals USA Inc — Parsippany, NJ

FDA drug recall D-1539-2022 was initiated by Teva Pharmaceuticals USA Inc on Aug 29, 2022 and is designated Class II. Reason for recall: Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product. The recall status is terminated (terminated Aug 14, 2023). Affected quantity: 83,703 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 21, 2022
Initiation Date
Aug 29, 2022
Termination Date
Aug 14, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
83,703 bottles

Product description

Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 15 mg, Rx Only, 100 tablets per bottle, Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0555-0777-02.

Reason for recall

Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.

Distribution pattern

Nationwide in the US.

Code information

Lot #: 100023340, Exp 10/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1539-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1539-2022. Report a data issue: hello@regdatalab.com.